前沿生物：公司不会转型为单一的早期研发授权型企业

Core Viewpoint - The company will not transition into a single early-stage research licensing entity, maintaining innovation as its core focus while leveraging both marketed innovative drugs and upcoming high-end generics for sustained cash flow to support R&D efforts [1] Group 1: Business Strategy - The recent collaboration in the small nucleic acid pipeline is viewed as a method for realizing pipeline value rather than a shift in business model [1] - The company plans to adopt a flexible business model in the small nucleic acid field, emphasizing the clinical value of products and selecting optimal paths for value realization based on product characteristics [1] Group 2: Collaboration and Development - The company aims to actively explore international collaborations with global pharmaceutical companies to leverage worldwide resources for market expansion [1] - For pipelines closely aligned with the company's long-term core strategy and where it possesses unique development advantages, the company will retain control and independently advance R&D and development efforts [1]